Researchers from Aker BioMarine have published a new pilot study on krill powder in Lipids in Health and Disease. The study, performed at Momentum Pharma Services GmbH, a CRO in Germany, and two academic research sites in Italy, investigated the effects of Superba(TM) Krill powder supplementation in obese subjects.
This new powder product, currently under development by Aker BioMarine Antarctic, provides phospholipid omega-3 fatty acids suitable for tablet applications.
For this particular study, 11 obese men underwent 24 weeks of treatment with Superba(TM) Krill powder. Then researchers assessed blood lipids and endocannabinoids as well as a variety of other parameters. Superba(TM) Krill powder reduced triglyceride levels by 21%. It also positively impacted three different endocannabinoids – a class of lipid signalling molecules that is dysregulated in obese subjects. In fact, one of the endocannabinoids – anandamide – which is elevated in obese subjects, decreased 84% by the end of treatment. Researchers also noted a significant decrease in the waist/hip ratio and visceral fat/skeletal muscle mass.
One of the co-authors, Vincenzo Di Marzo, PhD, commented on the study. “These results confirm previous findings with krill oil, demonstrating a reduction of an overactive endocannabinoid system in obese subjects. Krill oil and krill powder could potentially both be useful in ameliorating metabolic syndrome.”
Study coordinator Kjetil Berge, PhD, R&D Director, Aker BioMarine Antarctic, added: “We are excited to publish another clinical study on krill further validating the health benefits of phospholipid bound EPA and DHA.”
Matts Johansen, Chief Operating Officer, Aker BioMarine Antarctic confirmed: “This study represents an important addition to our overall krill research portfolio and we believe a free-flowing powder version of Superba(TM) will open up new market opportunities.”
Development of the powder version of Superba(TM) is ongoing with no commercial launch date set yet.
Aker BioMarine is a krill ingredient company that is primary in its supply. It’s proprietary Eco-Harvesting(TM) technology and on-board processing result in the unique composition of Superba(TM) Krill Oil and provides full traceability from sea to shelf. The Marine Stewardship Council (MSC) has granted MSC Certification to Aker’s fisheries, an exclusive distinction that no other krill fishery has earned. As part of an established commitment to substantiating krill’s health benefits, Aker continues to sponsor in vitro, in vivo, and human clinical trials with phospholipid EPA & DHA from krill oil, consistently demonstrating a higher uptake of phospholipid omega-3 fatty acids, improved blood lipid profiles, and increased uptake of DHA in brain tissue compared to other omega-3 fatty acid sources.
Berge, K. et al., “Chronic treatment with krill powder reduces plasma triglyceride and anandamide levels in mildly obese men” Lipids in Health and Disease. 2013,12:78
About SuperbaTM Krill
SuperbaTM Krill is a pure, natural source of the health-promoting EPA & DHA omega-3 essential fatty acids and the naturally occurring antioxidant astaxanthin. The uniqueness of SuperbaTM Krill Oil is that the omega-3 fatty acids are provided in phospholipid form. In vitro, in vivo and human clinical research has demonstrated the safety and efficacy of SuperbaTM Krill Oil.
About Aker BioMarine
Aker BioMarine is an integrated biotechnology company dedicated to the sustainable harvesting of krill and development of krill-derived biotech products. The company supplies biomarine ingredients through an optimized value chain from raw materials to customers. Aker BioMarine’s SuperbaTM Krill products are provided with 100-percent traceability from the Antarctic sea to the end user. Only Aker’s krill fishery has been awarded Marine Stewardship Council (MSC) Certification.
For more information, please contact:
Matts Johansen, COO, Aker BioMarine, +47 916 30 120.
Todd Norton, +1 206-855-6736 x 215
Roar Hernes, +47 (241) 30123
Chris McReynolds, +1 206-660-6756
Lalen Dogan, +61-3-9999-1112